Trajan Scientific and Medical (Trajan) and the University of Melbourne have embarked on an investigative collaboration today in the fields of molecular pathology and skin cancer diagnostics.
Molecular testing techniques can be used to pursue more accurate cancer screening and disease diagnosis.
Trajan’s emerging tools in micro sampling, sample preparation and mass spectrometry interfaces have generated strong interest in these healthcare applications.
Eight Master of Biotechnology students from the University’s Faculty of Science will be undertaking two industry projects in these areas, with guidance from Trajan mentors Mr Paul Romeo, General Manager, Australia and New Zealand, and Mr Stephen Tomisich, Chief Executive Officer.
"We look forward to fresh insights from the teams, which will help shape Trajan’s roadmap for diagnostic technologies.” said Mr Tomisich.
Academic and industry partnerships are key to Trajan’s collaborative model for innovation, accelerating delivery of scientific and medical solutions to the market that will make a positive impact on human wellbeing.
Photo (L-R): The University of Melbourne student teams at Trajan Global Headquarters in Melbourne, Australia. Paul Romeo (General Manager, Australia and New Zealand, Trajan), Keerthi Kalyan Kothapally, Seumas Shu Men Teh, Angela Tomisich (General Manager, Microscopy Products, Trajan), Robert Lyon (Head of Corporate Development, Trajan), Elpis Barons (General Manager, Accelerator Group, Trajan), Fiona Simpson (Careers and Industry Consultant, The University of Melbourne), Dr Andrew Gooley (Chief Scientific Officer, Trajan), Benjamin Nicholas Le Couteur, Belinda Bich Thuy Thieu Quang, Yanling Wu, Kairui Li, Jie Dong, Jingran Zhang, Rhonda Gailey (Assistant Manager, Corporate Development, Trajan), Dr Matthew Digby (Subject Coordinator, The University of Melbourne), Stephen Tomisich (Chief Executive Officer, Trajan).
Trajan Scientific and Medical’s hemaPEN® microsampling technology has been developed with extensive consultation and evaluation by leading analytical laboratories, clinicians and healthcare professionals.
This month, Trajan presents an exclusive interview with researcher Dr Michele Protti of Pharmaco-Toxicological Analysis, Bologna, Italy, on the future of microsampling and the critical role hemaPEN can play when used in therapeutic drug monitoring for optimal therapy personalization.
Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.